Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report

Mohajeri-Tehrani, Mohammad Reza; Ebrahimpur, Mahbube; Nasseri‐Moghaddam, Siavosh; Tavangar, Seyed-Mohammad; Sani, Mahnaz Pejman; Zandi, Abdollah; Shadmehr, Mohammad Behgam

doi:10.1007/s40200-022-01067-3

Cited by 1 publication

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent prospective clinical trials exploring high-dose SSA and a case report on octreotide-LAR treatment for metastatic non-functioning pancreatic tumors indicate reduced tumor growth and progression. [173], [174], [175], [176], [177], [178], [179] Pentetreotide, a drug utilized for visualizing somatostatin receptor-positive neuroendocrine tumors, is a small molecule. Functioning as an inhibitor of somatostatin receptors, it comes provided in a package with Indium-111and serves used as a contrast medium for imaging somatostatin receptor-positive neuroendocrine tumors, including specific pancreatic tumors.…”

Section: Antiviral Medicationmentioning

confidence: 99%

“…Recent studies highlight the affinity of Octreotide nanoparticles for in vivo induction of pancreas ductal adenocarcinoma using MIA Paca-2, indicating its potential utility in targeted therapy for pancreatic cancer. [121], [178], [187], [188] Leucovorin, classified as a folic acid analog, shares similarities with the vitamin folic acid, crucial for new cell production and maintenance. When combined with specific chemotherapy drugs, Leucovorin enhances their efficacy in eradicating cancer cells or mitigating adverse side effects.…”

Section: Other Treatment Strategymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Parichehreh,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundMalignant neoplasm of the pancreas (MNP), a highly lethal illness with bleak outlook and few therapeutic avenues, entails numerous cellular transformations. These include irregular proliferation of ductal cells, activation of stellate cells, initiation of epithelial-to-mesenchymal transition, and changes in cell shape, movement, and attachment. Discovering potent drug cocktails capable of addressing the genetic and protein factors underlying pancreatic cancer’s development is formidable due to the disease’s intricate and varied nature.MethodIn this study, we introduce a fresh model utilizing Graph Attention Networks (GATs) to pinpoint potential drug pairings with synergistic effects for MNP, following the RAIN protocol. This protocol comprises three primary stages: Initially, employing Graph Neural Network (GNN) to suggest drug combinations for disease management by acquiring embedding vectors of drugs and proteins from a diverse knowledge graph encompassing various biomedical data types, such as drug-protein interactions, gene expression, and drug-target interactions. Subsequently, leveraging natural language processing to gather pertinent articles from clinical trials incorporating the previously recommended drugs. Finally, conducting network meta-analysis to assess the relative effectiveness of these drug combinations.ResultWe implemented our approach on a network dataset featuring drugs and genes as nodes, connected by edges representing their respective p-values. Our GAT model identified Gemcitabine, Pancrelipase Amylase, and Octreotide as the optimal drug combination for targeting the human genes/proteins associated with this cancer. Subsequent scrutiny of clinical trials and literature confirmed the validity of our findings. Additionally, network meta-analysis confirmed the efficacy of these medications concerning the pertinent genes.ConclusionBy employing GAT within the RAIN protocol, our approach represents a novel and efficient method for recommending prominent drug combinations to target proteins/genes associated with pancreatic cancer. This technique has the potential to aid healthcare professionals and researchers in identifying optimal treatments for patients while also unveiling underlying disease mechanisms.HighlightsGraph Attention Networks (GATs) used to recommend drug combinations for pancreatic cancerRAIN protocol applied to extract relevant information from clinical trials and literatureGemcitabine, Pancrelipase Amylase, and Octreotide identified as optimal drug combinationNetwork meta-analysis confirmed the effectiveness of the drug combination on gene targetsNovel and efficient method for drug discovery and disease mechanism elucidationAbstract Figure

show abstract

Section: Antiviral Medicationmentioning

confidence: 99%

Section: Other Treatment Strategymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Parichehreh,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report

Cited by 1 publication

References 9 publications

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Contact Info

Product

Resources

About